Literature DB >> 2493429

Efficacy of ciprofloxacin alone and in combination with azlocillin in experimental endocarditis due to Pseudomonas aeruginosa.

C Thauvin1, F Lecomte, I Le Boete, G Grise, J F Lemeland.   

Abstract

The efficacy of ciprofloxacin alone and in combination with azlocillin was compared with that of azlocillin plus tobramycin in a rat model of aortic valve endocarditis due to Pseudomonas aeruginosa. MICs against the infecting strain of ciprofloxacin, azlocillin and tobramycin were 0.125, 8, and 0.5 mg/l, respectively. Antimicrobials were administered 24 h after bacterial challenge and for six days. Mean peak/trough serum levels for ciprofloxacin (50 mg/kg i.v. q 12 h), azlocillin (500 mg/kg i.v. q 12 h) and tobramycin (6.5 mg/kg i.v. q 12 h) were: 10.5/0.2, 386/less than 16, and 6.2/less than 0.6 mg/l, respectively. Ciprofloxacin alone was more effective than the combination azlocillin-tobramycin in increasing survival (p less than 0.05), sterilizing blood (p less than 0.05) and valves (p less than 0.001), and in reducing bacterial titers in vegetations (p less than 0.001). Ciprofloxacin-azlocillin combination was not more effective than ciprofloxacin alone. Drug resistance was not encountered in post-treatment isolates with any therapy regimen.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2493429     DOI: 10.1007/bf01643497

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  24 in total

Review 1.  Infective endocarditis caused by gram-negative bacteria: a review of the literature, 1945-1977.

Authors:  P S Cohen; J H Maguire; L Weinstein
Journal:  Prog Cardiovasc Dis       Date:  1980 Jan-Feb       Impact factor: 8.194

2.  Studies on antibiotic synergism against enterococci. I. Bacteriologic studies.

Authors:  R C Moellering; C Wennersten; A N Weinberg
Journal:  J Lab Clin Med       Date:  1971-05

3.  Ciprofloxacin in experimental Pseudomonas aeruginosa meningitis in rabbits.

Authors:  C J Hackbarth; H F Chambers; F Stella; A M Shibl; M A Sande
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

4.  Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats.

Authors:  C Thauvin; G M Eliopoulos; S Willey; C Wennersten; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

5.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

6.  In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.

Authors:  G M Eliopoulos; A Gardella; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

7.  Comparison of ciprofloxacin with azlocillin plus tobramycin in the therapy of experimental Pseudomonas aeruginosa endocarditis.

Authors:  R W Strunk; J C Gratz; R Maserati; W M Scheld
Journal:  Antimicrob Agents Chemother       Date:  1985-09       Impact factor: 5.191

8.  The comparative in-vitro activity of eight newer quinolones and nalidixic acid.

Authors:  A King; I Phillips
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

9.  Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo.

Authors:  F J McLaughlin; W J Matthews; D J Strieder; B Sullivan; A Taneja; P Murphy; D A Goldmann
Journal:  J Infect Dis       Date:  1983-03       Impact factor: 5.226

10.  Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.

Authors:  H Giamarellou; N Galanakis; C Dendrinos; J Stefanou; E Daphnis; G K Daikos
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

View more
  1 in total

Review 1.  Quinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance.

Authors:  A Dalhoff
Journal:  Infection       Date:  1994       Impact factor: 3.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.